Cargando…
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway
The protein lysine methyltransferase SMYD2 has recently emerged as a new enzyme modulate gene transcription or signaling pathways, and involved into tumor progression. However, the role of SMYD2 in drug resistant is still not known. Here, we found that inhibition of SMYD2 by specific inhibitor could...
Autores principales: | Shang, Lei, Wei, Minjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498871/ https://www.ncbi.nlm.nih.gov/pubmed/31106145 http://dx.doi.org/10.3389/fonc.2019.00306 |
Ejemplares similares
-
SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner
por: Lv, Hong-Wei, et al.
Publicado: (2021) -
p53 inhibits CTR1-mediated cisplatin absorption by suppressing SP1 nuclear translocation in osteosarcoma
por: Yong, Lei, et al.
Publicado: (2023) -
Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022) -
Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012) -
p53 Affects PGC1α Stability Through AKT/GSK-3β to Enhance Cisplatin Sensitivity in Non-Small Cell Lung Cancer
por: Deng, Xinyue, et al.
Publicado: (2020)